Related Experiment Video

Updated: Dec 24, 2025

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

5.4K

Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma

Tarek H Mouhieddine1, Yasir Ahmad2, Bart Barlogie3

  • 1Department of Medicine, Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, New York, NY.

Clinical Lymphoma, Myeloma & Leukemia
|April 9, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CXCR4/SDF-1 (CXCL12)Extramedullary diseaseHigh-risk cytogeneticsMyeloma cell homing, Myelomatous infiltration

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.3K
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

17.0K

Related Experiment Videos

Last Updated: Dec 24, 2025

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

5.4K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.3K
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

17.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K

Articles linked to this work by shared authors, journal, and citation graph.

Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.

Blood neoplasia·2026

Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.

Clinical lymphoma, myeloma & leukemia·2026

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

Nature medicine·2026

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

Future oncology (London, England)·2026

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Leukemia & lymphoma·2026

Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026

Real-World Experience With Mogamulizumab for Mycosis Fungoides and Sézary Syndrome.

Clinical lymphoma, myeloma & leukemia·2026

A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes.

Clinical lymphoma, myeloma & leukemia·2026

Testicular Plasmacytoma: A 25-Year Experience From a High-Volume Tertiary Center and Comparative Review of the Literature.

Clinical lymphoma, myeloma & leukemia·2026

SOHO State of the Art Updates and Next Questions | The Role of Maintenance Therapy Following Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026

Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type.

Clinical lymphoma, myeloma & leukemia·2026

A scalable outpatient framework for BI-RADS 2-4B breast nodule management: an iodine-DMSO transdermal protocol.

Frontiers in health services·2026

Spontaneous rupture of the urinary bladder and hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a case report.

Journal of surgical case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us